OXUR Oxurion NV
Oxurion NV, a biopharmaceutical company, develops medicines for vascular retinal disorder in Belgium. The company is developing ophthalmic treatments to preserve vision for patients geographic atrophy and wet age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.…
Industry Peers
BiotechnologyKey Statistics
About Oxurion (EBR: OXUR)
›
Oxurion (EBR: OXUR) is listed on Euronext Brussels, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 26 employees.
The shares were at 0.0010 EUR on 19 November 2026, down 91.9% over 52 weeks. Its 52-week range is 0.0006 EUR to 0.0124 EUR: the price is 91.9% below the high and 66.7% above the low.
Its market capitalisation is 232.00K EUR.
Oxurion reports return on equity of 28.9% and an operating margin of -196.5%.
Its debt exceeds its cash by 11.48M EUR. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.